10-Q: Nutriband Reports Wider Q3 Loss Amid R&D Shift, CEO Absence

Nutriband Inc. reported a significantly wider net loss for the three and nine months ended October 31, 2025, driven by increased expenses and a preferred stock dividend, despite an increase in cash and working capital.

Summary

• Net loss for the three months ended October 31, 2025, widened to $3,872,367 ($0.32 per share) from $1,362,637 ($0.12 per share) in the prior year.
• Net loss for the nine months ended October 31, 2025, increased to $7,261,573 ($2.54 per share after preferred stock dividend) from $4,966,179 ($0.48 per share) in the prior year.
• Revenue for the three months decreased to $346,058 from $645,796, primarily due to a principal customer moving operations to Asia.
• Revenue for the nine months increased to $1,635,942 from $1,497,158, driven by increased demand in the Pocono Pharmaceuticals segment.
• Selling, general and administrative expenses significantly increased to $3,491,728 for the three months and $6,071,320 for the nine months, primarily due to compensation-based and equity-based expenses.
• Research and development expenses decreased to $457,113 for the three months and $1,703,093 for the nine months, mainly due to a reduction in labor costs.
• Cash and cash equivalents increased to $5,312,177 as of October 31, 2025, from $4,311,719 as of January 31, 2025.
• Working capital improved to $5,042,529 as of October 31, 2025, from $3,811,420 as of January 31, 2025.
• A preferred stock dividend of 3,008,643 shares of Series A Convertible Preferred Stock, valued at $21,814,166, was issued on July 25, 2025.
• The company's disclosure controls and procedures are not effective due to a lack of segregation of duties, insufficient qualified accounting personnel, and over-reliance on third-party consultants.
• CEO Gareth Sheridan stepped aside for three months (August-October 2025) to participate in the Irish Presidential election campaign, with Co-Founder Serguei Melnik assuming interim CEO responsibilities.

Sentiment

Score: 3

Explanation: The company reported significantly wider net losses and increased cash burn from operations, primarily due to higher SG&A expenses and the impact of a large preferred stock dividend. While cash and working capital improved due to financing activities, and R&D costs decreased, the decline in Q3 revenue and ongoing material weaknesses in internal controls are concerning. The long-term potential of the AVERSA technology is positive, but the current financial performance and operational challenges indicate a high-risk profile.

Positives

• Cash and cash equivalents increased to $5,312,177 as of October 31, 2025, from $4,311,719 as of January 31, 2025.
• Working capital improved to $5,042,529 as of October 31, 2025, from $3,811,420 as of January 31, 2025.
• Nine-month revenue increased to $1,635,942 from $1,497,158, with an expected increase in demand for the balance of the current year in the Pocono Pharmaceuticals segment.
• Research and development expenses decreased for both the three and nine-month periods, primarily due to a reduction in labor costs.
• Management believes the substantial doubt about the company's ability to continue as a going concern is alleviated by current cash and expected operational funding for the next year.
• The agreement with Kindeva Drug Delivery for AVERSA Fentanyl was amended to reduce hourly labor rates, with a $3.0 million milestone payment contingent on FDA approval.
• The company has added qualified accounting personnel and improved internal controls to address previous material weaknesses.

Negatives

• Net loss significantly widened for both the three-month ($3,872,367 vs $1,362,637) and nine-month ($7,261,573 vs $4,966,179) periods compared to the prior year.
• Net loss available to common stockholders for the nine months was substantially higher at $29,075,739 due to a preferred stock dividend.
• Revenue for the three months ended October 31, 2025, decreased by 46.4% to $346,058 from $645,796 in the prior year, attributed to a principal customer moving operations to Asia.
• Gross profit decreased for the three-month period to $68,505 from $191,029.
• Selling, general and administrative expenses increased significantly by 373.7% for the three months and 137.7% for the nine months, primarily due to compensation and equity-based expenses.
• Cash used in operating activities increased to $4,402,800 for the nine months ended October 31, 2025, from $3,387,320 in the prior year.
• Interest income decreased for both periods, primarily due to cash used in the company's development operations.
• The company's disclosure controls and procedures are not effective due to material weaknesses, including a lack of segregation of duties and excessive reliance on third-party consultants.
• No sales were generated from the 4P Therapeutics segment in the current year due to a shift in focus and the main contract winding down.

Risks

• Economic uncertainty regarding U.S. economic policies may affect costs and timing of FDA approval processes.
• Operating results could be affected by current political and economic uncertainties related to the U.S. economy, domestic pharmaceutical industry, and world economies.
• Market instability could make it more difficult to forecast future product demand trends.
• Inflationary factors (increased costs to purchase products, acquire product rights, and overhead) may adversely affect operating results.
• Subject to risks common to low-revenue start-up enterprises, including undercapitalization, cash shortages, and limitations with personnel.
• Drug development companies typically incur substantial losses during product development and FDA testing phases and do not generate revenues until after FDA approval, which cannot be assured.
• Cannot assure profitability or positive cash flow; may be forced to cease operations, leading to a total loss of investment.
• Cannot predict when or whether the company will operate profitably as the lead product (AVERSA Fentanyl) is not yet developed or marketed in the United States.
• Substantial expenses are expected for product development and clinical trials, and additional required studies could increase expenses and delay product approval.
• Ability to obtain necessary funding to develop proposed products.
• Success of clinical trials for products.
• Ability to obtain FDA approval to market any proposed product in the United States.
• Delays in regulatory review and approval of products in development.
• Ability to establish manufacturing and distribution operations or enter into agreements with qualified third parties if FDA approval is obtained.
• Market acceptance of products.
• Ability to establish an effective sales and marketing infrastructure.
• Ability to protect intellectual property.
• Competition from existing or new products.
• Potential product liability claims and adverse events.
• Ability to adequately support future growth.
• Ability to attract and retain key personnel.
• Stock price has been and is likely to continue to be volatile, and shares may not be resold at or above the purchase price.
• Stockholders may experience significant dilution from future equity offerings and other issuances of common stock or other securities.
• The drug delivery industry is subject to rapid technological change, and failure to keep up with developments may impair the ability to market products, potentially rendering them obsolete.

Future Outlook

The company targets an NDA filing with the FDA for its AVERSA Fentanyl product in 2026. Management expects increased demand in the Pocono Pharmaceuticals segment for the balance of the current year, despite a decrease in Q3 revenue due to a customer moving operations. Management believes current cash and expected operational funding will sustain operations for one year from the filing date, alleviating going concern doubts.

Management Comments

• Management has prepared estimates for operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company's ability to continue operations as a going concern.
• Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.
• Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.
• We have expanded our development pipeline to include AVERSA Buprenorphine and AVERSA Methylphenidate.
• The revenue from the Pocono Pharmaceuticals segment decreased from the prior year as one of the Company's principal customers moved their operations to Asia. A decrease in demand is expected in the balance of the current year.
• There were no sales in our 4P Therapeutics segment in the current year due to a shift in focus and the main contract wound down in the prior year.
• The increase in gross margin is due primarily to higher margins in our sales mix.
• The increase [in SG&A] from 2024 is primarily attributable to increases in compensation-based expenses.
• The decrease [in R&D] is primarily attributable to a reduction in labor costs.
• The decrease [in interest income for 3 months] is primarily due to a decrease in cash used in the Company's operations.
• The decrease [in interest income for 9 months] is primarily due to cash used in the Company development operations.

Industry Context

Nutriband operates in the specialized drug delivery industry, focusing on transdermal pharmaceutical products, particularly those with abuse-deterrent technology. The company's AVERSA technology aims to address the critical public health issue of opioid and stimulant abuse, a significant area of focus for regulatory bodies like the FDA. The partnership with Kindeva Drug Delivery, a global CDMO, aligns with industry trends of outsourcing specialized manufacturing and development to leverage expertise and manage costs. The expansion of the AVERSA pipeline to include Buprenorphine and Methylphenidate indicates a strategic move to broaden the application of its core technology to other high-abuse potential drugs, positioning itself within a niche but high-impact segment of the pharmaceutical market. The challenges faced, such as the need for substantial funding and the lengthy FDA approval process, are typical for early-stage drug development companies in this highly regulated sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against.
• Drug development companies, especially those in early clinical stages like Nutriband with its AVERSA Fentanyl, typically incur substantial losses and negative cash flow, which is consistent with Nutriband's reported financials.
• The reliance on equity financing and warrant exercises for funding is standard for pre-revenue or low-revenue biotech/pharma companies.
• The lengthy and costly FDA approval process, including preclinical and clinical trials, is a universal challenge in the pharmaceutical industry, making the 2026 NDA target ambitious but within typical timelines for such products.
• The identified material weaknesses in internal controls, particularly regarding segregation of duties and reliance on consultants, are below industry best practices for publicly traded companies, though the company states it is addressing these.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in a lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP in the Supreme Court of the State of New York, New York County (Index No.654633/2023).
• Allegations include breach of contract, fraudulent activities, and tortious interference, seeking over $500,000 in damages plus punitive damages and legal fees.
• The company denies all allegations, claiming the engagement letter was unenforceable and termination was justified.
• The company has initiated counterclaims against Joseph Gunnar & Co. for intentional interference and breach of fiduciary duty, seeking $1,000,000 for each claim.
• The case is in the discovery stage, and a $100,000 settlement offer from plaintiffs has not been responded to by the company.

Related Party Transactions

• A director and a related party exercised warrants, resulting in the issuance of 311,041 and 160,000 shares of common stock, respectively, during the nine months ended October 31, 2025.
• In August 2025, 409,167 options to purchase common shares were issued to executive officers and employees, exercisable at $6.22-$6.85 per share, with a fair value of $1,285,137.
• In October 2025, the President and CFO exercised employee stock options, with the President exchanging options for settlement of $317,110 of debt by issuing 120,000 common shares.
• In October 2025, 340,393 warrants were issued to investors for services rendered, including a director and a related party, with a non-cash expense of $1,250,264.
• In April 2024, related parties invested $7,120,000 in an $8,400,000 equity financing, receiving 1,780,000 common shares and warrants to purchase 3,560,000 common shares.
• In May 2024, the company converted $300,000 debt and accrued interest from TII Jet Services LDA (a related party credit line facility) into 76,240 common shares and 152,460 warrants.

Stakeholder Impact

• Shareholders: Experience significant dilution from the preferred stock dividend and potential future equity raises. The widening net loss and increased cash burn could negatively impact share price. The legal proceedings introduce uncertainty.
• Employees/Executives: Benefited from stock options and warrants issued for services, providing compensation and incentives.
• Customers (Pocono Pharmaceuticals): One principal customer moved operations to Asia, impacting Q3 revenue, indicating potential customer retention challenges.
• Creditors: The conversion of related-party debt into equity reduces debt obligations but introduces equity dilution. The secured borrowing liability related to a bankruptcy claim carries a risk of repayment if the claim is not paid in full.
• Regulatory Authorities (FDA): The company's primary strategic focus is on obtaining FDA approval for its AVERSA products, which is critical for future revenue generation and market access.

Next Steps

• NDA filing with the FDA for AVERSA Fentanyl targeted for 2026.
• Continue product development program, including preclinical and clinical trials for AVERSA Fentanyl, AVERSA Buprenorphine, and AVERSA Methylphenidate.
• Address material weaknesses in disclosure controls and procedures by continuing to add qualified accounting personnel and improving internal controls.
• Resolve the ongoing legal proceedings with Joseph Gunnar, LLC and Lucosky Brookman LLP.
• Potentially raise additional capital through equity offerings or other securities to fund product development.

Key Dates

Recommendation

Nutriband presents a mixed financial picture. While the company has improved its cash position and working capital, primarily through financing activities, and is making progress on its AVERSA Fentanyl development with a target NDA filing in 2026, the significant widening of net losses and increased cash burn from operations are concerning. The substantial increase in SG&A expenses and the impact of the preferred stock dividend on common stockholder net loss per share highlight operational inefficiencies and dilution. The identified material weaknesses in internal controls add a layer of risk. The long-term potential of the AVERSA abuse-deterrent technology is a key driver, but its success is contingent on FDA approval and market acceptance, which are uncertain. Given the high-risk, early-stage nature of its core pharmaceutical business, coupled with current financial underperformance and governance issues, a "hold" recommendation is appropriate. Investors should monitor progress on FDA approval, improvements in internal controls, and the resolution of legal proceedings before considering further investment. The stock is speculative, and while there's potential upside from AVERSA, the current risks and financial results warrant caution.

Keywords

Nutriband Inc., NTRB, 10-Q, Quarterly Report, SEC Filing, Pharmaceuticals, Transdermal Patches, Drug Delivery, AVERSA Technology, Abuse Deterrent, Fentanyl, Buprenorphine, Methylphenidate, Kindeva Drug Delivery, FDA Approval, Clinical Trials, Pocono Pharmaceuticals, 4P Therapeutics, Financial Results, Net Loss, Revenue, R&D Expenses, SG&A Expenses, Working Capital, Cash Flow, Going Concern, Stock Options, Warrants, Preferred Stock Dividend, Corporate Governance, Internal Controls, Legal Proceedings, Share Price Volatility, Dilution Risk